Home
Join A Case
Contact
More
Class Action Cases
Akorn, Inc.
According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Akorn’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’s acquisition of Akorn; (2) Akorn lacked effective internal controls over financial reporting; and (3) as a result, Akorn’s financial statements were materially false and misleading at all relevant times. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.
Press Release
Case has been filed